A phase i study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): An NRG oncology/gynecologic oncology group study

D. Scott McMeekin, Michael W. Sill, Joan L. Walker, Kathleen N. Moore, Steven E. Waggoner, Premal H. Thaker, Tina Rizack, James S. Hoffman, Paula M. Fracasso

Research output: Contribution to journalComment/debate

Original languageEnglish
Pages (from-to)626-628
Number of pages3
JournalObstetrical and Gynecological Survey
Issue number10
StatePublished - 2015

Cite this